Pharmacologic Management of Type 2 Diabetes in Advanced Chronic Kidney Disease (eGFR 20–30 mL/min/1.73 m²)
1. SGLT2‑Inhibitor Use
- Continue dapagliflozin 10 mg daily for cardiovascular and kidney protection even when eGFR is 20–30 mL/min/1.73 m², despite minimal glucose‑lowering effect. 2
- Ongoing dapagliflozin therapy reduces CKD progression, cardiovascular death, and heart‑failure hospitalization independently of glycaemia. 4
- A reversible decline in eGFR may occur after dapagliflozin initiation and should not prompt discontinuation. 6
- Dapagliflozin can be maintained even if eGFR falls below 20 mL/min/1.73 m² until the patient requires dialysis. 6
- Withhold dapagliflozin during prolonged fasting, surgery, or critical illness to avoid ketoacidosis. 6
- Monitor volume status before and after initiating or adjusting dapagliflozin because of potential volume depletion. 3
2. DPP‑4‑Inhibitor Use
- Reduce sitagliptin dose to 25 mg once daily when eGFR is 20–30 mL/min/1.73 m². 2
- DPP‑4 inhibitors are well tolerated and carry minimal hypoglycemia risk in advanced CKD. 5
- Linagliptin can be used without dose adjustment across all CKD stages. 1
3. Sulfonylurea (Gliclazide) Considerations
- Sulfonylureas such as gliclazide have a high risk of hypoglycemia in advanced CKD and should be used cautiously or discontinued. 1
- If glycemic control allows, taper or stop gliclazide before adding additional glucose‑lowering agents. 7
4. GLP‑1 Receptor Agonist (GLP‑1 RA) Addition
- A long‑acting GLP‑1 RA is the preferred add‑on when metformin and SGLT2i are insufficient or contraindicated. 1
4.1 Agent‑Specific Recommendations
| Agent | Dose‑adjustment requirement | Minimum eGFR for use | Initiation & titration (starting → target) |
|---|---|---|---|
| Dulaglutide | None | > 15 mL/min/1.73 m² | 0.75 mg weekly → may increase to 1.5 mg weekly |
| Liraglutide | None | No specific lower limit (generally safe) | 0.6 mg daily → titrate to 1.2–1.8 mg daily |
| Semaglutide (injectable) | None | No specific lower limit | 0.25 mg weekly → titrate to 0.5–1 mg weekly |
- All GLP‑1 RAs provide effective glucose lowering irrespective of kidney function. 8
- They have a low intrinsic risk of hypoglycemia. 1
- Outcome trials demonstrate cardiovascular risk reduction. 2
- They slow eGFR decline and reduce albuminuria. 9
- Weight loss is an additional benefit. 10
- Initiate at the lowest dose and titrate slowly to minimize gastrointestinal adverse effects. 1
5. Other Oral Options (When GLP‑1 RA Not Tolerated)
- Acarbose – No dose adjustment needed for eGFR 30–44 mL/min/1.73 m²; not recommended when eGFR < 30 mL/min/1.73 m². 2
- Pioglitazone – No dose adjustment across CKD stages, but contraindicated in patients with heart failure due to fluid‑retention risk. 11
6. Metformin Discontinuation
- Metformin must be stopped when eGFR falls below 30 mL/min/1.73 m² because of lactic‑acidosis risk. 1
7. Monitoring & Safety Practices
- Check eGFR at least every 3–6 months in patients with eGFR 20–30 mL/min/1.73 m². 1
- Educate patients on recognizing and managing hypoglycemia, especially when sulfonylureas are being reduced or stopped. 8
- Provide sick‑day guidance (withhold SGLT2i during fasting, surgery, or acute illness). 3
- Assess volume status and consider reducing concomitant diuretic doses if signs of dehydration appear. 6
8. Role of Insulin
- Insulin remains an appropriate and often necessary therapy for advanced CKD when oral agents fail to achieve glycemic targets. 1
- However, the combination of continued dapagliflozin, dose‑adjusted DPP‑4 inhibitor, and added GLP‑1 RA can provide substantial glucose‑lowering, cardiovascular, and renal protection, potentially deferring the need for insulin. 2